Clinical study of medical devices for quantifying and/or classifying motor deficits in patients with Parkinson’s disease or essential tremor - Clinical study for ANLIVA™ Dyskinesia & ANLIVA™ Eye Movement
Not Applicable
Completed
- Conditions
- Parkinson's disease and essential tremorNervous System Diseases
- Registration Number
- ISRCTN82413223
- Lead Sponsor
- Stardots AB
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 80
Inclusion Criteria
1. Patients already diagnosed with PD or ET or Healthy volunteers
2. Able to understand and sign the informed consent.
Exclusion Criteria
1. No signing of the informed consent
2. Below 18 years of age
3. Involvement in the planning and conduct of the clinical investigation (applies to all Stardots management staff, investigational staff and third-party vendors as applicable).
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms underlying tremor quantification using smartphone sensors in Parkinson's disease?
How does ANLIVA™ Dyskinesia compare to standard-of-care assessments for hyperkinesia in essential tremor patients?
Are there specific biomarkers that correlate with ocular motor deficits measured by advanced tracking cameras in Parkinson's disease?
What adverse events are associated with mobile sensor-based monitoring in neurological disorders like essential tremor?
What are the potential advantages of combining ANLIVA™ Eye Movement analysis with existing Parkinson's disease diagnostic tools?